fig1

From: Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy

Figure 1. Violin plots of propensity score (PS) (A) before and after (B) 1:1 nearest neighbor matching (caliper of 0.1 standard deviations of the logit of PS) and (C) weighting using average treatment effect of the treated (ATT) in a simulated cohort of 100 tenofovir disoproxil fumarate (TDF)-treated patients and 900 entecavir (ETV)-treated patients with chronic hepatitis B. PS was estimated by logistic regression of seven covariates to predict the use of TDF.

fig1

Portico

Portico